The recovery from taxane mediated apoptosis in PC-3 castration-resistant metastatic prostate cancer cells

被引:1
|
作者
Eskiler, Gamze Guney [1 ]
Ozkan, Asuman Deveci [1 ]
Elmas, Merve Acikel [2 ]
Ozturk, Melek [3 ]
Arbak, Serap [2 ]
机构
[1] Sakarya Univ, Fac Med, Dept Med Biol, Korucuk Campus, TR-54290 Sakarya, Turkiye
[2] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Histol & Embryol, Istanbul, Turkiye
[3] Istanbul Cerrahpasa Univ, Fac Med, Dept Med Biol, Istanbul, Turkiye
关键词
Castration resistant metastatic prostate cancer; cells; Drug resistance; Apoptosis; Taxanes; Cabazitaxel; DNA-DAMAGE; CABAZITAXEL;
D O I
10.1016/j.tiv.2024.105894
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Here, we revealed the reversibility of cabazitaxel (CBZ)-induced apoptosis in PC-3 castration resistant metastatic prostate cancer cells (mCRPC) through the hallmarks of apoptosis. The recovery of PC-3 cells from apoptosis upon removal of CBZ at different recovery periods was evaluated by Annexin V, DNA damage, oxidative damage, mitochondrial membrane depolarization, and caspase activation. Our results showed that the administration of CBZ caused apoptosis for 72 h in PC-3 cells. However, recovered cells exhibited decreased nuclear damage, plasma membrane disruption, ROS level, release cytochrome c level and caspase-3 activation with upregulation of Bcl-2 expression upon removal of especially 1 nM CBZ for 24 h recovery period in PC-3 cells. Our study indicates that CBZ treated PC-3 cells can recover after apoptotic cell death. However, advanced molecular analysis should elucidate the relationship between the molecular mechanisms of recovery and taxane response or resistance in PC-3 mCRPC cells.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Re: Olaparib for Metastatic Castration-resistant Prostate Cancer
    Di Lorenzo, Giuseppe
    Autorino, Riccardo
    EUROPEAN UROLOGY, 2020, 78 (05) : 767 - 768
  • [32] Contemporary management of metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Sternberg, Cora N.
    CURRENT OPINION IN UROLOGY, 2011, 21 (03) : 241 - 247
  • [33] Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
    Bumbaca, Brandon
    Lin, Wei
    ACTA PHARMACEUTICA SINICA B, 2018, 8 (04) : 518 - 529
  • [34] Histologic Spetrum of Metastatic Castration-Resistant Prostate Cancer
    Huang, Jiaoti
    Yin, Yu
    Thomas, George
    True, Lawrence
    Beer, Tomasz M.
    Gleeve, Martin
    Witte, Owen
    Stuart, Josh
    Evans, Chris
    Foye, Adam
    Youngren, Jack
    Small, Eric
    LABORATORY INVESTIGATION, 2017, 97 : 231A - 231A
  • [35] The obesity paradox in metastatic castration-resistant prostate cancer
    Martini, Alberto
    Shah, Qainat N.
    Waingankar, Nikhil
    Sfakianos, John P.
    Tsao, Che-Kai
    Necchi, Andrea
    Montorsi, Francesco
    Gallagher, Emily J.
    Galsky, Matthew D.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (03) : 472 - 478
  • [36] Drug resistance in metastatic castration-resistant prostate cancer
    Bostjan Seruga
    Alberto Ocana
    Ian F. Tannock
    Nature Reviews Clinical Oncology, 2011, 8 : 12 - 23
  • [37] Re: Olaparib for Metastatic Castration-resistant Prostate Cancer
    Cumberbatch, Marcus
    Condon, Benjamin
    Lawrentschuk, Nathan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2021, 79 (02) : 319 - 320
  • [38] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
  • [39] Drug resistance in metastatic castration-resistant prostate cancer
    Seruga, Bostjan
    Ocana, Alberto
    Tannock, Ian F.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (01) : 12 - 23
  • [40] Histologic Spetrum of Metastatic Castration-Resistant Prostate Cancer
    Huang, Jiaoti
    Yin, Yu
    Thomas, George
    True, Lawrence
    Beer, Tomasz M.
    Gleeve, Martin
    Witte, Owen
    Stuart, Josh
    Evans, Chris
    Foye, Adam
    Youngren, Jack
    Small, Eric
    MODERN PATHOLOGY, 2017, 30 : 231A - 231A